These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32510680)

  • 1. Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial.
    Galadanci NA; Abdullahi SU; Ali Abubakar S; Wudil Jibir B; Aminu H; Tijjani A; Abba MS; Tabari MA; Galadanci A; Borodo AM; Belonwu R; Salihu AS; Rodeghier M; Ghafuri DL; Covert C Greene BV; Neville K; Kassim AA; Kirkham FJ; Jordan LC; Aliyu MH; DeBaun MR
    Am J Hematol; 2020 Sep; 95(9):E247-E250. PubMed ID: 32510680
    [No Abstract]   [Full Text] [Related]  

  • 2. Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial.
    Abdullahi SU; DeBaun MR; Jordan LC; Rodeghier M; Galadanci NA
    Pediatr Neurol; 2019 Jun; 95():73-78. PubMed ID: 30952488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial).
    Galadanci NA; Umar Abdullahi S; Vance LD; Musa Tabari A; Ali S; Belonwu R; Salihu A; Amal Galadanci A; Wudil Jibir B; Bello-Manga H; Neville K; Kirkham FJ; Shyr Y; Phillips S; Covert BV; Kassim AA; Jordan LC; Aliyu MH; DeBaun MR
    Am J Hematol; 2017 Aug; 92(8):780-788. PubMed ID: 28439953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial.
    Abdullahi SU; Jibir BW; Bello-Manga H; Gambo S; Inuwa H; Tijjani AG; Idris N; Galadanci A; Hikima MS; Galadanci N; Borodo A; Tabari AM; Haliru L; Suleiman A; Ibrahim J; Greene BC; Ghafuri DL; Rodeghier M; Slaughter JC; Kirkham FJ; Neville K; Kassim A; Trevathan E; Jordan LC; Aliyu MH; DeBaun MR
    Lancet Haematol; 2022 Jan; 9(1):e26-e37. PubMed ID: 34971579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary stroke prevention in Nigerian children with sickle cell disease (SPIN): challenges of conducting a feasibility trial.
    Galadanci NA; Abdullahi SU; Tabari MA; Abubakar S; Belonwu R; Salihu A; Neville K; Kirkham F; Inusa B; Shyr Y; Phillips S; Kassim AA; Jordan LC; Aliyu MH; Covert BV; DeBaun MR
    Pediatr Blood Cancer; 2015 Mar; 62(3):395-401. PubMed ID: 25399822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishing Sickle Cell Disease Stroke Prevention Teams in Africa is Feasible: Program Evaluation Using the RE-AIM Framework.
    Ghafuri DL; Abdullahi SU; Dambatta AH; Galadanci J; Tabari MA; Bello-Manga H; Idris N; Inuwa H; Tijjani A; Suleiman AA; Jibir BW; Gambo S; Gambo AI; Khalifa Y; Haliru L; Abdulrasheed S; Zakari MA; Greene BC; Trevathan E; Jordan LC; Aliyu MH; Baumann AA; DeBaun MR
    J Pediatr Hematol Oncol; 2022 Jan; 44(1):e56-e61. PubMed ID: 34001783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and Safety of Hydroxyurea in the Treatment of Sickle Cell Anaemia Children in Jos, North Central Nigeria.
    Ofakunrin AOD; Oguche S; Adekola K; Okpe ES; Afolaranmi TO; Diaku-Akinwumi IN; Zoakah AI; Sagay AS
    J Trop Pediatr; 2020 Jun; 66(3):290-298. PubMed ID: 31608959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Annual stroke incidence in Nigerian children with sickle cell disease and elevated TCD velocities treated with hydroxyurea.
    Lagunju I; Brown BJ; Oyinlade AO; Asinobi A; Ibeh J; Esione A; Sodeinde OO
    Pediatr Blood Cancer; 2019 Mar; 66(3):e27252. PubMed ID: 29797633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary prevention of stroke in children with sickle cell anemia in sub-Saharan Africa: rationale and design of phase III randomized clinical trial.
    Abdullahi SU; Wudil BJ; Bello-Manga H; Musa AB; Gambo S; Galadanci NA; Aminu H; Tijjani Gaya A; Sanusi S; Tabari MA; Galadanci A; Borodo A; Abba MS; Dambatta AH; Haliru L; Gambo A; Cassell H; Rodeghier M; Ghafuri DL; Covert Greene BV; Neville K; Kassim AA; Kirkham F; Trevathan E; Jordan LC; Aliyu MH; DeBaun MR
    Pediatr Hematol Oncol; 2021 Feb; 38(1):49-64. PubMed ID: 33236662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcranial Doppler screening in Nigerian children with sickle cell disease: A 10-year longitudinal study on the SPPIBA cohort.
    Lagunju IA; Labaeka A; Ibeh JN; Orimadegun AE; Brown BJ; Sodeinde OO
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28906. PubMed ID: 33522690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
    John CC; Opoka RO; Latham TS; Hume HA; Nabaggala C; Kasirye P; Ndugwa CM; Lane A; Ware RE
    N Engl J Med; 2020 Jun; 382(26):2524-2533. PubMed ID: 32579813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyurea lowers transcranial Doppler flow velocities in children with sickle cell anaemia in a Nigerian cohort.
    Lagunju I; Brown BJ; Sodeinde O
    Pediatr Blood Cancer; 2015 Sep; 62(9):1587-91. PubMed ID: 25847050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial.
    Abdullahi SU; Sunusi S; Abba MS; Sani S; Inuwa HA; Gambo S; Gambo A; Musa B; Covert Greene BV; Kassim AA; Rodeghier M; Hussaini N; Ciobanu M; Aliyu MH; Jordan LC; DeBaun MR
    Blood; 2023 Feb; 141(8):825-834. PubMed ID: 36322937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Maximum tolerated dose" vs "fixed low-dose" hydroxyurea for treatment of adults with sickle cell anemia.
    Akingbola TS; Tayo BO; Ezekekwu CA; Sonubi O; Zhang X; Saraf SL; Molokie R; Hsu LL; Han J; Cooper RS; Gordeuk VR
    Am J Hematol; 2019 Apr; 94(4):E112-E115. PubMed ID: 30663794
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
    Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE
    Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approximately 40 000 children with sickle cell anemia require screening with TCD and treating with hydroxyurea for stroke prevention in three states in northern Nigeria.
    Galadanci AA; Galadanci NA; Jibir BW; Abdullahi SU; Idris N; Gambo S; Ali Abubakar SA; Kabo NA; Bello-Manga H; Haliru L; Bashir I; Aliyu MH; Galadanci JA; DeBaun MR
    Am J Hematol; 2019 Nov; 94(11):E305-E307. PubMed ID: 31423630
    [No Abstract]   [Full Text] [Related]  

  • 17. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.
    Strouse JJ; Lanzkron S; Beach MC; Haywood C; Park H; Witkop C; Wilson RF; Bass EB; Segal JB
    Pediatrics; 2008 Dec; 122(6):1332-42. PubMed ID: 19047254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience.
    Gulbis B; Haberman D; Dufour D; Christophe C; Vermylen C; Kagambega F; Corazza F; Devalck C; Dresse MF; Hunninck K; Klein A; Le PQ; Loop M; Maes P; Philippet P; Sariban E; Van Geet C; Ferster A
    Blood; 2005 Apr; 105(7):2685-90. PubMed ID: 15604217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease.
    George A; Dinu B; Estrada N; Minard CG; Hurwitz R; Mahoney DH; Yates AM; Vaughan M; Carmouche A; Airewele G; Kirk SE; Fasipe T; Uwaezuoke P; Ware RE
    Am J Hematol; 2020 Sep; 95(9):E242-E244. PubMed ID: 32472611
    [No Abstract]   [Full Text] [Related]  

  • 20. Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic.
    Nickel RS; Margulies S; Frazer B; Luban NLC; Webb J
    Blood; 2020 Jun; 135(25):2320-2322. PubMed ID: 32403134
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.